Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- FDA proposes to ban nitroglycerin patches
- In a brief Federal Register notice, the FDA proposed in March to withdraw its approval of six nitroglycerin transdermal products for lack of proof of bioavailability/bioequivalence and invited their manufacturers to seek a hearing. The notice is part of the tail-end of the FDAs Drug Efficacy Study Implementation DESI program...
- Research articles 1999-05-01
- FDA approves skin patch for adult depression.
- Smoking and birth control patches are already widely used and doctors will soon be able to prescribe patches for adult depression. The Food and Drug Administration announced Feb. 28 the approval of Emsam, the first skin patch for treating major depre Smoking and birth control patches...
- Research articles 2006-03-10
- Shire's Daytrana Patch Recall Is 8th So Far: Time to Pull the Plug?
- Shire SHPGY has voluntarily recalled the Daytrana ADHD patch citing problems with patients removing the liner on the back. It is not a safety issue, the company says. Daytrana is for children with ADHD; it is the only patch product to treat the condition. "Sudden death" is one of the...
- Blog posts 2009-12-07
- Dermisonics' Test With Type 2-Diabetics Proves Insulin Isn't Transported Through the Skin When Patch Not Activated by Ultrasound; Represents Another Step Forward in Achieving FDA Approval.
- IRVINE, CALIFORNIA, Oct 3, 2006 CCNMatthews via COMTEX -- Dermisonics, Inc. (OTCBB:DMSI)(FWB:FQC), a pioneer in the development of painless injection-free ultrasonic transdermal drug-delivery patches and technologies with broad pharmaceutical and c IRVINE, CALIFORNIA, Oct 3, 2006 CCNMatthews via COMTEX -- Dermisonics, Inc. (OTCBB:DMSI)(FWB:FQC), a pioneer...
- Research articles 2006-10-03
Additional Resources
- Omrix Biopharmaceuticals Inc. Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. And our first question will come from the line of Amit Hazan with Oppenheimer, please proceed. Amit Hazan - Oppenheimer Thanks. Hi, Good Morning guys. Robert Taub Good Morning Amit Sophie Hobbs Good morning Amit. Amit Hazan - Oppenheimer First question...
- Earnings calls 2008-05-09
- Should We Be Surprised That Schering-Plough Execs Are "Surprised" By Sugammadex Rejection?
- Yet another setback for Schering-Plough seems to have taken top management by surprise. Schering’s shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia-recovery drug would not be approved by the FDA. In a statement, Schering VP Thomas Koestler said he was “surprised...
- Blog posts 2008-08-01
- << Previous
- page 1 of 1
- Next >>
Presented by the Premiere Rewards Gold Card from American Express